Manufacturing

The pharmaceutical landscape is undergoing a radical transformation as the era of blockbuster drugs for the masses gives way to a highly specialized approach designed for individuals with unique genetic mutations. This paradigm shift was catalyzed by the landmark case of Mila Makovec, who faced a

The current oncology landscape faces a persistent bottleneck as traditional chimeric antigen receptor T-cell therapies continue to struggle with the immunosuppressive defenses of solid tumors. While liquid cancers have seen remarkable recovery rates, the dense extracellular matrix and hostile

Medical facilities currently face a significant bottleneck where patients with aggressive hematological malignancies must wait weeks for personalized cell manufacturing while their conditions deteriorate rapidly. The established autologous model requires extracting a patient's own T-cells,

The biopharmaceutical landscape in 2026 operates as a high-stakes arena where the efficiency of protein production directly determines the accessibility of life-saving treatments for millions of patients. Central to this enterprise are Chinese hamster ovary (CHO) cells, which currently serve as the

The persistent challenge of managing generalized myasthenia gravis has long forced patients to rely on treatments that merely suppress symptoms rather than addressing the underlying immune dysfunction that causes debilitating muscle weakness. Kyverna Therapeutics and ElevateBio have recently

Trauma surgeons often face a race against time when a patient presents with a shattered limb or a ruptured artery where every second spent searching for a viable donor vein increases the risk of amputation or death. This high-pressure environment has long necessitated a surgical solution that